CVS Accused Of Revealing HIV Status Of 4,000 Ohio Customers

Published on

CVS Accused Of Revealing HIV Status Of 4,000 Ohio Customers

By Ashlee Kieler, CONSUMERIST

August 31, 2017

Days after insurance giant Aenta was accused of revealing the HIV medication use of 12,000 customers, CVS has found itself in a similar boat: The pharmacy giant allegedly sent letters to customers that inadvertently revealed their HIV status.

CVS Caremark confirmed to Consumerist that the company recently mailed pharmacy benefit information to approximately 4,000 members of Ohio’s AIDS Drug Assistance Program. Those letters visibly referenced HIV.

The mailing campaign has since been discontinued.

ADAP pays for HIV medication for low-income consumers without insurance, or whose insurance won’t cover the medication.

One envelope viewed by The Blade included the notation “PM 6402 HIV” above a customer’s name and address, visible through the window of the envelope.

A rep for CVS tells Consumerist that the reference code was intended to refer to the name of the program, not the customer’s health status.

“CVS Health places the highest priority on protecting the privacy of our patients and we take our responsibility to safeguard confidential patient information very seriously,” the rep said. “We immediately halted the mailings and are currently taking steps to eliminate the reference to the plan name in any future mailings.”

The AIDS activist who provided a copy of the mailing to The Blade urges customers affected by the letters to contact the state’s ADAP coordinator to report what he considers a breach of clients’ privacy.

Ashlee Kieler@akieler

Consumer Watchdog
Consumer Watchdog
Providing an effective voice for American consumers in an era when special interests dominate public discourse, government and politics. Non-partisan.

Other Litigation Areas

Latest Litigation Articles

Litigation In The News

Support Consumer Watchdog

Subscribe to our newsletter

To be updated with all the latest news, press releases and special reports.

More Litigation articles